BJDX · Bluejay Diagnostics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $811.8K | - | $785.6K | $889.9K | $784.8K | - | $551.7K | $1.03M | $1.33M | - |
| SG&A | $1.13M | - | $831.3K | $1.10M | $1.10M | - | $809.2K | $862.5K | $6.4K | - |
| Total Operating Expenses | $1.94M | - | $1.62M | $1.99M | $1.89M | - | $1.36M | $1.90M | $2.43M | - |
| D&A | $27.8K | - | - | - | $18.4K | - | - | - | $19.7K | - |
| Operating Income | ($1.94M) | - | ($1.62M) | ($1.99M) | ($1.89M) | - | ($1.36M) | ($1.90M) | ($2.43M) | - |
| Interest Expense | - | - | $190.6K | $626.5K | - | - | $185.9K | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.92M) | - | ($1.60M) | ($1.96M) | ($1.86M) | - | ($1.48M) | ($2.48M) | ($2.33M) | - |
| EPS - Basic | ($1.95) | - | ($4.04) | ($5.64) | ($13.48) | - | ($32.00) | ($1024.00) | ($1584.00) | - |
| EPS - Diluted | ($1.95) | - | ($4.04) | ($5.64) | ($13.48) | - | ($32.00) | ($1024.00) | ($1584.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.68M | $5.16M | $3.08M | $4.44M | $3.12M | $4.30M | $5.76M | $8.06M | $2.66M | $2.21M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $220.3K | $214.3K | $161.2K | $108.8K | $519.5K | $145.1K | $316.6K | $490.1K | $271.8K | $491.5K |
| Current Assets | $3.97M | $5.46M | $3.35M | $4.75M | $3.57M | $4.90M | $6.57M | $9.02M | $3.45M | $3.22M |
| Total Assets | $5.60M | $7.12M | $4.89M | $6.40M | $5.28M | $6.66M | $8.35M | $10.86M | $5.08M | $4.87M |
| Current Liabilities | $1.41M | $1.12M | $1.15M | $1.04M | $1.32M | $810.4K | $1.05M | $2.06M | $1.53M | $1.77M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.42M | $1.14M | $1.20M | $1.11M | $1.41M | $927.9K | $1.19M | $2.22M | $1.71M | $1.97M |
| Stockholders' Equity | $4.18M | $5.98M | $3.69M | $5.29M | $3.87M | $5.73M | $7.16M | $8.64M | $3.37M | $2.89M |
| Retained Earnings | ($43.44M) | ($41.52M) | ($40.09M) | ($38.49M) | ($36.53M) | ($34.67M) | ($33.24M) | ($31.75M) | ($29.28M) | ($26.95M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.59M) | - | - | - | ($1.18M) | - | - | - | ($2.30M) | - |
| Investing Cash Flow | ($15.3K) | - | - | - | - | - | - | - | ($35.4K) | - |
| Financing Cash Flow | $124.1K | - | - | - | ($985) | - | - | - | $2.78M | - |
| CapEx | $19.0K | - | - | - | - | - | - | - | $35.4K | - |
| Free Cash Flow | ($1.61M) | - | - | - | - | - | - | - | ($2.33M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.84 | - | - | - | - | - | - | - | 1.00 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -34.3% | - | -32.7% | -30.6% | -35.3% | - | -17.7% | -22.8% | -45.9% | - |
| Return on equity | -45.9% | - | -43.3% | -37.0% | -48.2% | - | -20.7% | -28.6% | -69.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.81 | 4.88 | 2.92 | 4.56 | 2.71 | 6.05 | 6.26 | 4.38 | 2.26 | 1.82 |
| Quick ratio | 2.81 | 4.88 | 2.92 | 4.56 | 2.71 | 6.05 | 6.26 | 4.38 | 2.26 | 1.82 |
| Cash ratio | 2.61 | 4.61 | 2.68 | 4.27 | 2.37 | 5.31 | 5.49 | 3.92 | 1.74 | 1.25 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -8.5x | -3.2x | - | - | -7.3x | - | - | - |
| Equity multiplier | 1.34 | 1.19 | 1.32 | 1.21 | 1.37 | 1.16 | 1.17 | 1.26 | 1.51 | 1.68 |
| Liabilities / Assets | 0.25 | 0.16 | 0.24 | 0.17 | 0.27 | 0.14 | 0.14 | 0.20 | 0.34 | 0.41 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.4x | - | 2.6x | 1.8x | 2.1x | - | 33.9x | 7.8x | 900.2x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -2.6% | - | -18.8% | -4.8% | 22.2% | - | 41.8% | 34.7% | 9.4% | - |
| Net income growth (YoY) | -2.9% | - | -7.8% | 21.0% | 19.9% | - | 35.5% | 12.0% | 8.3% | - |
| EPS growth (YoY) | 85.5% | - | 87.4% | 99.4% | 99.1% | - | -1438.5% | -37136.4% | -1583900.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 28.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 8.1% | 4.3% | -48.5% | -38.8% | 14.8% | 97.9% | 37.4% | 35.5% | -63.3% | -74.9% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Bluejay Diagnostics against the 5 most active filers in the same SIC group.